Joana Fernandes, PhD,  —

Treatment with Alcresta Therapeutics’ product Relizorb effectively increased fat absorption in patients with cystic fibrosis (CF) receiving enteral tube feeding who have trouble breaking down and absorbing these molecules. This resulted in a reduction of the frequency and severity of gastrointestinal symptoms. These findings were published recently in the…

Electromed recently launched a SmartVest Connect wireless technology to complement the SmartVest SQL, a technology that allows doctors and patients with certain lung diseases, such as cystic fibrosis or bronchiectasis, to have access to treatment information and collaborate in care decisions. The device developed by Electromed, the SmartVest Airway Clearance…

In September 2016, Jerry Cahill and Emily Schaller joined a high-profile effort to persuade cystic fibrosis patients like themselves to cycle to improve their health. The title of the event said it all: It was the third annual Bike to Breathe adventure. Convinced that cycling helps them combat a disease…

Synspira’s SNSP113 gives antibiotics more punch against the Burkholderia cepacia infections that cystic fibrosis patients experience, a study reports. The research, published in PLoS One, was titled “Novel glycopolymer sensitizes Burkholderia cepacia complex isolates from cystic fibrosis patients to tobramycin and meropenem.” Lung infections caused by Burkholderia cepacia are difficult to…

A deeper understanding of how bacteria like Pseudomonas aeruginosa acts and survives in people despite antibiotic treatment was the focus of a doctoral thesis, along with a recommendation for antibiotic combinations that might work better those what’s currently in use. The thesis, “Host-pathogen interactions in Pseudomonas aeruginosa invasive and respiratory tract infection,” is by…

Proteostasis Therapeutics has filed an Investigational New Drug application with the U.S. Food and Drug Administration for PTI-808 as a treatment for cystic fibrosis. PTI-808 promotes the activity of the cystic fibrosis transmembrane conductance regulator, or CFTR, the protein that is faulty in CF. Scientists call the drug a potentiator…

Spyryx Biosciences will present two studies in Washington this week on SPX-101‘s ability to treat cystic fibrosis by clearing mucus from airways. One of the preclinical-trial studies it will discuss at the American Thoracic Society‘s annual convention showed that SPX-101 improved survival in several models of CF-like lung diseases.

The naturally occurring molecule thymosin α1 (Tα1) reversed tissue defects in mice with cystic fibrosis (CF) and in human cells that contained a mutation associated with the disease, according to a study. The findings mean that Tα1 could be a promising treatment for CF patients carrying the F508del mutation in…

Spyryx Biosciences presented new data and updates on its cystic fibrosis (CF) treatment SPX-101 at two recent events: the European Cystic Fibrosis Society Basic Science Conference, which took place March 29-April 1 in Albufeira, Portugal, and the invitation-only Needham & Company’s 16th Annual Healthcare Conference, held April 4-5 in New…

Stem cell therapy may reduce lung inflammation in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD), according to preliminary results of a pre-clinical-trial study. The findings, presented at this year’s Lung Science Conference in Estoril, Portugal, could lead to new ways to treat the diseases. The title of…